Home › Targets › 5-HT2A
5-HT2A (3 companies · 16 programs)
Companies with an active program directed at 5-HT2A.
- brilaroxazine — Schizophrenia Phase 3
- brilaroxazine — Bipolar Disorder
- brilaroxazine — Major Depressive Disorder
- brilaroxazine — Attention-Deficit/Hyperactivity Disorder
- brilaroxazine — Behavioral and Psychotic Symptoms of Dementia
- brilaroxazine — Parkinson's Disease Psychosis
- brilaroxazine — Pulmonary Arterial Hypertension Preclinical
- brilaroxazine — Idiopathic Pulmonary Fibrosis Preclinical
- brilaroxazine — Psoriasis Preclinical
- mebufotenin — Treatment-Resistant Depression Phase 3
- R-MDMA — Social Anxiety Disorder Phase 2
- EGX-A — Treatment-Resistant Depression Preclinical
- EGX-A — Opioid Use Disorder Preclinical
- DT120 ODT — Generalized Anxiety Disorder Phase 3
- DT120 ODT — Major Depressive Disorder Phase 3
- DT120 ODT — Posttraumatic Stress Disorder Phase 3
